FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of March 2026
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
Notice of AGM
10
March 2026
Notice of Annual General Meeting
AstraZeneca PLC (the Company) announced today the publication of
its Notice of Annual General Meeting 2026 and Shareholders'
Circular (the Notice).
The Company's Annual General Meeting (AGM) will be
digitally-enabled and will be held on Thursday 9 April 2026 at
14:30 (BST). Full details and joining instructions are set out in
the Notice.
The Notice, proxy form and 2020 Performance Share Plan rules have
been submitted to the National Storage Mechanism and will shortly
be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
The Notice is also available on the Company's website
at www.astrazeneca.com/noticeofmeeting2026.
The Notice is being despatched to shareholders today.
The business to be conducted at the AGM is summarised
below:
1.
To receive the Company's Accounts, the Reports of the
Directors and Auditor and the Strategic Report for the year ended
31 December 2025
2.
To confirm the 2025 interim dividends
3.
To appoint KPMG LLP as Auditor
4.
To authorise the Directors to agree the remuneration of the
Auditor
5.
To re-elect Directors
6.
To approve the annual statement of the Chair of the
Remuneration Committee and the Annual Report on
Remuneration for the year ended 31 December 2025
7.
To renew the authorisation to grant awards under the French
Appendix 3 of the AstraZeneca Performance Share Plan
2020
8.
To authorise limited political donations
9.
To authorise the Directors to allot shares
10.
To authorise the Directors to disapply pre-emption
rights
11.
To authorise the Directors to further disapply pre-emption rights
for acquisitions and specified capital investments
12.
To authorise the Company to purchase its own shares
13. To
reduce the notice period for general meetings
Holders of ordinary shares listed on the New York Stock
Exchange entered
in the register of members of the Company by 18:30 (BST) on 7 April
2026 (or their duly appointed proxies), or if this meeting is
adjourned, in the register of members by 18:30 (UK time) two UK
business days prior to any adjourned meeting, are entitled to
participate and vote at the AGM in respect of the number of
ordinary shares registered in their name at that
time.
Holders of AstraZeneca PLC UK Depositary Interests (UK DIs) in the
AstraZeneca PLC Corporate Sponsored Nominee facility (CSN
Holders) entered
in the Company's register of CSN Holders (the CSN Register) as at
18:00 (BST) on 1 April 2026 or, if the meeting is adjourned, at
18:00 (UK time) on the day which is four UK business days before
the day of the adjourned meeting, shall be entitled to provide
voting instructions to Computershare Investor Services Plc (in
accordance with the notes set out in the Notice) in respect of the
number of UK DIs that such holders are beneficially entitled to at
that time.
Registered holders of UK DIs other
than UK DIs held via the AstraZeneca PLC Corporate Sponsored
Nominee facility (UK DI Holders) entered
in the Company's register of UK DI Holders (the DI Register) as
at 18:00 (BST) on 1 April 2026 or, if the meeting is
adjourned, at 18:00 (UK time) on the day which is four UK business
days before the day of the adjourned meeting, shall be entitled to
provide voting instructions to Computershare Investor Services Plc
(in accordance with the notes set out in the Notice) in respect of
the number of UK DIs registered in their name at that
time.
The Record Date applied to the Euroclear Sweden
system for
this AGM is close of business on 27 March 2026. Holders
of ordinary shares listed on Nasdaq Stockholm at the Record Date
are entitled to vote and participate in the AGM in respect of the
number of shares held at the Record Date.
Changes to the entries in the: (i) register of members of the
Company; (ii) CSN Register; (iii) DI Register; or (iv) records held
in the Euroclear Sweden system, after the respective record dates
and times set out above, shall be disregarded in determining the
rights of any person to participate or vote at the
AGM.
Holders of ordinary shares or UK DIs through a nominee account,
broker or bank should refer to the information provided by their
account provider (as well as the notes set out in the Notice) for
the relevant voting deadlines that apply to them.
AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca's innovative
medicines are sold in more than 125 countries and used by millions
of patients worldwide. Please visit astrazeneca.com and
follow the Company on social media @AstraZeneca
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
Matthew Bowden
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
AstraZeneca
PLC
|
Date: 10 March 2026
|
|
By: /s/
Matthew Bowden
|
|
|
Name:
Matthew Bowden
|
|
|
Title:
Company Secretary
|